TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12668373

Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 48277

Group type: EXPERIMENTAL
Intervention: Other antidepressants
Number of subjects: 48277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48277
Study: 10659559

Group type: EXPERIMENTAL
Intervention: Sharp dissection
Number of subjects: 94

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 94
Study: 8754401

Group type: EXPERIMENTAL
Intervention: EPO treated patients (12 patients, HD for 138 +/- 66 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (14 patients, HD for 121 +/- 35 months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: EPO group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 1985006

Group type: EXPERIMENTAL
Intervention: 20 mg of domperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6831839

Group type: EXPERIMENTAL
Intervention: 8% ethanol (v/v in saline)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Salbutamol (400 micrograms by aerosol)
Number of subjects: 5
Study: 30954363

Group type: EXPERIMENTAL
Intervention: NUTRITION
Number of subjects: 81

Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 81
Study: 29691288

Group type: COMPARATOR
Intervention: Prehypertension
Number of subjects: 29439

Group type: COMPARATOR
Intervention: Stage 1 Hypertension
Number of subjects: 29439

Group type: COMPARATOR
Intervention: Stage 2 Hypertension
Number of subjects: 29439

Group type: COMPARATOR
Intervention: Stage 3 Hypertension
Number of subjects: 29439

Group type: COMPARATOR
Intervention: Rise in BP from normotension to hypertension
Number of subjects: 29439

Group type: COMPARATOR
Intervention: Rise in BP from prehypertension to hypertension
Number of subjects: 29439
Study: 26011050

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 80
Study: 23240939

Group type: EXPERIMENTAL
Intervention: 0.5% acemannan in Carbopol® 934P NF
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide
Number of subjects: 180

Group type: COMPARATOR
Intervention: pure Carbopol® 934P NF
Number of subjects: 180
Study: 20650490

Group type: COMPARATOR
Intervention: Shock wave lithotripsy (SWL) using Compact Delta II lithotriptor
Number of subjects: 100
Study: 18959683

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 168
Study: 17586832

Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation with single embryo transfer (n = 197)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Standard GnRH agonist long-protocol ovarian stimulation with double embryo transfer (n = 194)
Number of subjects: 253
Study: 12940501

Group type: EXPERIMENTAL
Intervention: Told-yes smokers (could smoke)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smokers with 15 s delay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smokers with 60 s delay
Number of subjects: 0
Study: 11107744

Group type: EXPERIMENTAL
Intervention: High-dose melphalan with autologous stem cell support
Number of subjects: 274
Study: 8818844

Group type: EXPERIMENTAL
Intervention: 250 mg tablets with food
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 500 mg suspension with food
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1000 mg sachet with food
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1000 mg sachet (absolute bioavailability)
Number of subjects: 3
Study: 1468240

Group type: EXPERIMENTAL
Intervention: etodolac SR 600 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: etodolac SR 1200 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 30
Study: 6204142

Group type: EXPERIMENTAL
Intervention: High sodium intake (200 mmol)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Reduced sodium intake (70 mmol)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: High sodium intake (200 mmol) in subjects over 50 years
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: High sodium intake (200 mmol) in younger individuals
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Increased sodium intake
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Reduced sodium intake
Number of subjects: 201
Study: 30630702

Group type: EXPERIMENTAL
Intervention: Problem Solving‐Adherence (PSA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Personalized Intervention for Depressed Patients with COPD (PID‐C)
Number of subjects: 87
Study: 29713133

Group type: COMPARATOR
Intervention: Catheter and guidewire (Group I)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Papillary fistulotomy (Group II)
Number of subjects: 102
Study: 26938358

Group type: EXPERIMENTAL
Intervention: Fluid intake self-management
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fluid intake self-efficacy
Number of subjects: 180
Study: 24163264

Group type: EXPERIMENTAL
Intervention: Insulin degludec (0.4 U/kg, single subcutaneous dose)
Number of subjects: 30
Study: 22253751

Group type: EXPERIMENTAL
Intervention: Educational and physical program (Intervention Group)
Number of subjects: 1913

Group type: COMPARATOR
Intervention: No intervention (Control Group)
Number of subjects: 1913
Study: 19953628

Group type: EXPERIMENTAL
Intervention: Provox Normal HME (R‐HME)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Provox HiFlow HME (L‐HME)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Without HME
Number of subjects: 11
Study: 17473095

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for >2 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Exclusive breastfeeding for <=2 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High maternal antibody levels in serum and breast milk
Number of subjects: 150
Study: 15061863

Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL) on oral cancer
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 1525
Study: 12173999

Group type: EXPERIMENTAL
Intervention: Calcium propionate (preservative code 282)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9665188

Group type: EXPERIMENTAL
Intervention: Four cycles of intensive chemotherapy (short arm)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Eight cycles of intensive chemotherapy (long arm)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Both treatment arms (short and long)
Number of subjects: 248
Study: 10150267

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (1 dose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (2 doses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (6 doses)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Control Group A)
Number of subjects: 120
Study: 2775391

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for diagnosing meniscal tears
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for diagnosing cruciate ligaments
Number of subjects: 23
Study: 1064904

Group type: EXPERIMENTAL
Intervention: Rapidly-disintegrating tablets with a standardized breakfast meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slow-release tablets with a standardized breakfast meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rapidly-disintegrating tablets under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slow-release tablets under fasting conditions
Number of subjects: 24
Study: 31431562

Group type: EXPERIMENTAL
Intervention: Advanced counseling (training device + smartphone application)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Verbal counseling
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Advanced counseling
Number of subjects: 371
Study: 31678957

Group type: EXPERIMENTAL
Intervention: Case Management (CM) plus Usual Intervention (UI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Intervention (UI) alone
Number of subjects: 0
Study: 28693599

Group type: EXPERIMENTAL
Intervention: 24/7 phone support intervention for 30 days post-discharge
Number of subjects: 286
Study: 26443663

Group type: EXPERIMENTAL
Intervention: Online Individual Development Account (IDA) for 6 months with financial incentives for saving
Number of subjects: 700

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 700
Study: 23362174

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control area (deltoid region)
Number of subjects: 24
Study: 21372569

Group type: EXPERIMENTAL
Intervention: HAT score 0-1
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HAT score 2
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HAT score 3
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HAT score 4-5
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HAT score
Number of subjects: 161
Study: 19276452

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 17915181

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training (20 sessions, 30-45 minutes each, twice a week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 16332654

Group type: EXPERIMENTAL
Intervention: Rye bread and pasta diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oat and wheat bread and potato diet
Number of subjects: 72
Study: 11563466

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution
Number of subjects: 695

Group type: COMPARATOR
Intervention: Vaginal dinoprostone (2mg, two doses administered six hours apart)
Number of subjects: 695
Study: 9638409

Group type: COMPARATOR
Intervention: Clamping of the hepatic pedicle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total vascular exclusion
Number of subjects: 0
Study: 8032457

Group type: EXPERIMENTAL
Intervention: Bone grafts (autografts and allografts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nongrafted sites
Number of subjects: 0
Study: 2686422

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200 mg twice daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ceftazidime 1 to 2 g every eight to 12 hours
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 52
Study: 31053081

Group type: COMPARATOR
Intervention: NoV group (no mechanical ventilation during CPB)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: LOV group (low VT of 3-4 ml/kg IBW, RR of 10-12 acts/min, PEEP of 5-8 cmH2O, FiO2 30%)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: HOV group (low VT of 3-4 ml/kg IBW, RR of 10-12 acts/min, PEEP of 5-8 cmH2O, FiO2 80%)
Number of subjects: 420
Study: 27859982

Group type: EXPERIMENTAL
Intervention: Anodal-tDCS (1 mA, 20 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-tDCS (30 s)
Number of subjects: 0
Study: 25872610

Group type: EXPERIMENTAL
Intervention: Losartan treatment for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan treatment (in independent trials IDNT and IRMA-2)
Number of subjects: 0
Study: 24026775

Group type: EXPERIMENTAL
Intervention: Frame-based stereotactic surgical planning system (SSPS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional frame-based stereotactics with urokinase thrombolysis
Number of subjects: 65
Study: 21488723

Group type: EXPERIMENTAL
Intervention: Desensitizing agent (5% potassium nitrate/2% sodium fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 19660004

Group type: COMPARATOR
Intervention: Omalizumab (anti-IgE antibody), subcutaneously administered, dosage not specified, duration of treatment not specified.
Number of subjects: 1933
Study: 16828295

Group type: EXPERIMENTAL
Intervention: On pump coronary artery bypass grafting
Number of subjects: 70

Group type: COMPARATOR
Intervention: Off pump coronary artery bypass grafting
Number of subjects: 70
Study: 15244210

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.
Number of subjects: 50
Study: 11831341

Group type: EXPERIMENTAL
Intervention: Moist heat application
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dry heat application
Number of subjects: 46
Study: 9792566

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All patient groups (CF and COPD)
Number of subjects: 36
Study: 7900628

Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2794839

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (100 mg/cup)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine capsules (100 mg/capsule)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 690226

Group type: EXPERIMENTAL
Intervention: Marijuana high dose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Marijuana low dose
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coltsfoot
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High dose marijuana in odor session
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low dose marijuana in odor session
Number of subjects: 48
Study: 31536112

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 301

Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 301
Study: 30702517

Group type: EXPERIMENTAL
Intervention: TDF/FTC/EFV on Alternate Days (ATAD)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC)
Number of subjects: 197
Study: 27003457

Group type: EXPERIMENTAL
Intervention: Amino acid administration
Number of subjects: 130

Group type: COMPARATOR
Intervention: Saline administration (Control)
Number of subjects: 130
Study: 26678938

Group type: EXPERIMENTAL
Intervention: Propofol TCI alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol TCI plus midazolam and fentanyl
Number of subjects: 100
Study: 23177515

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg daily
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 199
Study: 21295286

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily (n = 55)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 19369829

Group type: EXPERIMENTAL
Intervention: Active treatment (omeprazole 20 mg once daily, clarithromycin 250 mg twice daily, tinidazole 500 mg twice daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Active treatment (among H. pylori eradicated patients)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (among patients with persistent H. pylori infection)
Number of subjects: 82
Study: 16688094

Group type: EXPERIMENTAL
Intervention: ARV + HU (Hydroxyurea 500 mg BID)
Number of subjects: 68

Group type: COMPARATOR
Intervention: ARV alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ARV + HU
Number of subjects: 68
Study: 15347128

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E) and cyclic norethisterone acetate (NETA)
Number of subjects: 16
Study: 11773673

Group type: EXPERIMENTAL
Intervention: Exercise plus acupuncture
Number of subjects: 35

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 35
Study: 9255270

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, adriamycin and vincristine (CAV)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (PE)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Alternating treatments of CAV and PE
Number of subjects: 286
Study: 8510386

Group type: EXPERIMENTAL
Intervention: Glucose in the dialysate (GD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No glucose in the dialysate (GFD)
Number of subjects: 8
Study: 31200280

Group type: EXPERIMENTAL
Intervention: Intentional invasive strategy with ischemia targeted reasonably complete coronary revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative medical therapy
Number of subjects: 0
Study: 29476677

Group type: EXPERIMENTAL
Intervention: Salivary osmolality in patients with CP (SG)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Caries experience (DMFT index) in patients with CP (SG)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Caries risk in patients with CP (SG)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Salivary osmolality cutoff point for SG
Number of subjects: 104

Group type: COMPARATOR
Intervention: Salivary osmolality cutoff point for CG
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Correlation between salivary osmolality and DMFT index in SG
Number of subjects: 104
Study: 27133564

Group type: EXPERIMENTAL
Intervention: YAB group (200 g of yoghurt supplemented with Bifidobacterium longum during both diet periods)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: YB group (yoghurt only during the balanced diet period)
Number of subjects: 33

Group type: COMPARATOR
Intervention: CTR group (no yoghurt intake)
Number of subjects: 33
Study: 24782624

Group type: EXPERIMENTAL
Intervention: Transparent cap group (n = 60)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (n = 108)
Number of subjects: 168
Study: 22122709

Group type: EXPERIMENTAL
Intervention: Single layer closure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Multilayer closure
Number of subjects: 61
Study: 20216071

Group type: EXPERIMENTAL
Intervention: Group F (follicular phase)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Group L (luteal phase)
Number of subjects: 72
Study: 18624972

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1,000 mg alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) + Dutasteride (D) 0.5 mg/die
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) + Letrozole (L) 2.5 mg/die
Number of subjects: 15
Study: 16440580

Group type: EXPERIMENTAL
Intervention: Calcipotriol solution 50 g/ml, applied twice daily for 8 weeks
Number of subjects: 22
Study: 12639589

Group type: EXPERIMENTAL
Intervention: Familiar screening scenarios without cost-effectiveness information
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Familiar screening scenarios with cost-effectiveness information
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Unfamiliar screening scenarios with cost-effectiveness information
Number of subjects: 900
Study: 10569667

Group type: EXPERIMENTAL
Intervention: Theophylline (adenosine receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 8905484

Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil (PA group; N = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam-alfentanil (MA group; N = 30)
Number of subjects: 60
Study: 1804948

Group type: EXPERIMENTAL
Intervention: HFPPV
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PTV
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both HFPPV and PTV
Number of subjects: 49
Study: 6364399

Group type: EXPERIMENTAL
Intervention: 12.5 mg tendamistate with 100 g maize meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 mg tendamistate with 100 g maize meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 mg tendamistate with 100 g maize meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo with 100 g maize meal
Number of subjects: 6
Study: 30194109

Group type: EXPERIMENTAL
Intervention: eTICI 3 (100% reperfusion)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: eTICI 2c (90-99% reperfusion)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: eTICI 2b67 (67-89% reperfusion)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: eTICI 2b50 (50-66% reperfusion)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: eTICI 2a (14-50% reperfusion)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: eTICI 1 (1-14% reperfusion)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: eTICI 0 (no reperfusion)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale shift analyses
Number of subjects: 801
Study: 30114726

Group type: EXPERIMENTAL
Intervention: Total Observed Caries Experience (TOCE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMFT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dmft
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevalence of untreated decay
Number of subjects: 0

Group type: COMPARATOR
Intervention: TOCE compared with controls
Number of subjects: 0
Study: 27506971

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtX‐A) injection (200 IU) in the quadriceps muscles
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (saline injection)
Number of subjects: 44
Study: 25002161

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 830

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Participants with PAD
Number of subjects: 830
Study: 23083041

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40